NURTEC ODT has two distinct adult uses: treating migraine attacks and preventing episodic migraine. The same orally disintegrating tablet can appear in different prescribed schedules, so the treatment purpose must stay clear.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | rimegepant sulfate (strength expressed as rimegepant) |
| Medicine class | Calcitonin gene-related peptide (CGRP) receptor antagonist |
| Forms and strengths | Orally disintegrating tablet: 75 mg, for oral or sublingual use |
Acute treatment and episodic prevention
The US label covers acute migraine with or without aura in adults and preventive treatment of episodic migraine in adults. Those are different treatment purposes. A preventive prescription should not be treated as an unlimited additional supply for attacks; the prescriber needs to specify how the medicine fits the whole migraine plan.
Source: [1]
Handling the dissolving tablet
The 75 mg tablet is placed on or under the tongue and dissolves without water. Use dry hands and peel the blister foil rather than pushing the tablet through. Take it immediately after opening. The prescribed schedule and label limits remain important even though only one tablet strength is listed.
Source: [1]
Allergy and circulation warnings
Serious hypersensitivity reactions, including breathing difficulty, can occur days after administration. Obtain urgent help for signs of a serious allergic reaction. The current label also warns about new or worsening hypertension and Raynaud's phenomenon. Report increased blood pressure or painful, cold or discolored fingers or toes to the treating team.
Source: [1]
Interactions can change dose spacing
Strong CYP3A4 inhibitors and strong or moderate CYP3A inducers should be avoided with rimegepant. Moderate CYP3A4 inhibitors and potent P-gp inhibitors have specific repeat-dose restrictions. Severe liver impairment and end-stage kidney disease also require attention. A pharmacist should check the exact medicines rather than treating all migraine tablets alike.
Source: [1]
Keep frequency within the prescribed plan
The label limits dosing to 75 mg in 24 hours and states that safety of more than 18 doses in 30 days is not established. These limits are not a target for personal use. Nausea and, with preventive treatment, abdominal discomfort are reported adverse effects. Review increasing treatment frequency with the prescribing team.
Further reading includes the NURTEC ODT and UBRELVY comparison. Its selected comparison facts do not provide a switching or dose-conversion plan.
Source: [1]
Questions and answers
Is NURTEC ODT only an attack treatment?
No. Its US label also includes preventive treatment of episodic migraine in adults, using a different schedule.
Should the tablet be pushed through its foil?
No. Peel back the foil with dry hands and remove the dissolving tablet gently.
Does one available strength mean the schedule is the same for everyone?
No. Treatment purpose and interactions affect instructions even though the cited tablet strength is 75 mg.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026